Vesicare Suspension
NDC Package 51248-250-99

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Vesicare (solifenacin succinate) suspension is solifenacin is used to treat an overactive bladder. This formulation utilizes a suspension delivery system. Marketed by Astellas Pharma Us, Inc., this product is identified by NDC 51248-250 and is authorized under FDA application NDA209529.

Identification & Billing

NDC Package Code
51248-250-99
Package Description
1 BOTTLE, PLASTIC in 1 CARTON / 150 mL in 1 BOTTLE, PLASTIC
Product Code
51248-250
11-Digit Billing Format
51248025099
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Vesicare LS
Non-Proprietary Name
Solifenacin Succinate
Substance Name
Solifenacin Succinate
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
SOLIFENACIN SUCCINATE 1 mg/mL
Pharmacologic Class
Usage Information
Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Regulatory & Marketing

Labeler Name
Astellas Pharma Us, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA209529
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-26-2020
End Marketing Date
07-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51248-250-99 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 150 ml in 1 bottle, plastic of Vesicare LS, a human prescription drug labeled by Astellas Pharma Us, Inc.. This suspension is formulated for oral use and contains solifenacin succinate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Astellas Pharma Us, Inc. on May 26, 2020.

What are the primary indications for this medication?

Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

How is this Astellas Pharma Us, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51248025099. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51248-250-99
11-Digit CMS (5-4-2)
51248-0250-99

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.